Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - TETRALOGIC PHARMACEUTICALS Corp | exh_991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 28, 2015
TetraLogic Pharmaceuticals Corporation
(Exact name of Registrant as specified in its charter)
| Delaware | 001-36208 | 42-1604756 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
343 Phoenixville Pike
Malvern, PA 19355
(610) 889-9900
(Address, Including Zip Code, and Telephone Number, Including
Area Code, of Registrant’s Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
The Company is furnishing a Corporate Presentation dated September 2015 (the “Corporate Presentation”), attached as Exhibit 99.1 hereto, which the Company may use from time to time beginning on September 28, 2015 in presentations to investors and other stakeholders. The Corporate Presentation will also be available on the Company’s website at http:/tlog.com.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits: | |
| 99.1 | Corporate Presentation dated September 2015 (furnished and not filed for purposes of Item 7.01). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: September 28, 2015 | TetraLogic Pharmaceuticals Corporation | |
| By: | /s/ Richard L. Sherman | |
| Name: Richard L. Sherman | ||
| Title: Senior Vice President, Strategic Transactions, General Counsel and Secretary | ||
EXHIBIT INDEX
|
Exhibit No. |
Description | |
| 99.1 | Corporate Presentation dated September 2015 (furnished and not filed for purposes of Item 7.01). |